ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Butalbital and acetaminophen (paracetamol): Pediatric drug information

Butalbital and acetaminophen (paracetamol): Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
ALERT: US Boxed Warning
Hepatotoxicity:

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 mg per day, and often involve more than one acetaminophen-containing product.

Brand Names: US
  • Allzital;
  • Bupap [DSC]
Therapeutic Category
  • Analgesic, Miscellaneous;
  • Barbiturate
Dosing: Pediatric

Note: Based on experience in adult patients, limit use to ≤3 days per month to avoid medication overuse headache (Ref). Multiple product formulations available; use precaution with product selection. All sources of acetaminophen (eg, prescription, OTC, combination products) should be considered when evaluating a patient's maximum daily dose. To lower the risk for hepatotoxicity, limit daily dose to ≤75 mg/kg/day (maximum of 5 daily doses), not to exceed 4,000 mg/day; while recommended doses are generally considered safe, hepatotoxicity has been reported (rarely) even with doses below recommendations (Ref).

Headache, tension or muscle contraction

Headache, tension or muscle contraction: Children ≥12 years and Adolescents:

Butalbital 25 mg/acetaminophen 325 mg: Oral: 2 tablets every 4 hours as needed; maximum daily dose: 12 tablets/24 hours (total: butalbital 300 mg/acetaminophen 3,900 mg per 24 hours).

Butalbital 50 mg/acetaminophen 300 or 325 mg: Oral: 1 or 2 tablets every 4 hours as needed; maximum daily dose: 6 tablets/24 hours (butalbital 300 mg/acetaminophen ≤1,950 mg per 24 hours).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment; see individual agents.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment; see individual agents.

Dosing: Adult

(For additional information see "Butalbital and acetaminophen (paracetamol): Drug information")

Note: Because barbiturates have been associated with medication-overuse headache, reserve use for patients without alternative treatment options (Ref). If used, limit butalbital use to ≤3 days per month to avoid medication-overuse headache (Ref); studies have found increased risk with use of ≥5 days per month (Ref).

Tension-type headache

Tension-type headache: Oral:

Butalbital 25 mg/acetaminophen 325 mg: 2 tablets every 4 hours as needed (maximum: 12 tablets [butalbital 300 mg/acetaminophen 3,900 mg] per 24 hours).

Butalbital 50 mg/acetaminophen 300 to 325 mg: 1 or 2 tablets every 4 hours as needed (maximum: 6 tablets [butalbital 300 mg/acetaminophen 1,950 mg] per 24 hours).

Discontinuation of therapy: For low butalbital doses or less frequent use, consider abrupt discontinuation of therapy or a gradual taper over 2 to 4 weeks. If use is frequent or at high doses or if a patient has developed chronic migraine, discontinuing the butalbital-containing product and replacing with a gradual (eg, over ~9 to 28 days) phenobarbital taper is advised to avoid withdrawal symptoms (ie, worsened headache, nausea/vomiting, restlessness, anxiety, diaphoresis, disturbed sleep, seizures). Consider providing bridge therapy with a medication to treat acute headaches and optimizing a preventative regimen to avoid rebound headache (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Also see acetaminophen.

Frequency not defined:

Cardiovascular: Syncope, tachycardia

Dermatologic: Hyperhidrosis, pruritus

Endocrine & metabolic: Hot flash

Gastrointestinal: Abdominal pain, constipation, dysphagia, flatulence, heartburn, nausea, vomiting, xerostomia

Genitourinary: Diuresis

Hepatic: Hepatic failure

Hypersensitivity: Hypersensitivity reaction

Nervous system: Agitation, confusion, depression, dizziness, drowsiness, euphoria, excitement, fatigue, headache, increased energy, intoxicated feeling, lethargy, numbness, sedated state, seizure, shakiness, tingling sensation

Neuromuscular & skeletal: Lower leg pain, muscle fatigue

Ophthalmic: Heavy eyelids

Otic: Otalgia, tinnitus

Respiratory: Dyspnea, nasal congestion

Miscellaneous: Fever

Postmarketing: Dermatologic: Erythema multiforme, toxic epidermal necrolysis

Contraindications

Hypersensitivity to butalbital, acetaminophen, or any component of the formulation; porphyria

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Hepatotoxicity: Risk is increased with alcohol use, preexisting liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.

• Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.

• Skin reactions: Rarely, acetaminophen may cause serious and potentially fatal skin reactions such as acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Discontinue treatment if severe skin reactions develop.

Disease-related concerns:

• Abdominal conditions: Use with caution in patients with acute abdominal conditions.

• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological, and physical dependence may occur with prolonged use.

• Ethanol use: Use with caution in patients with alcoholic liver disease; consuming ≥3 alcoholic drinks per day may increase the risk of liver damage.

• G6PD deficiency: Use with caution in patients with known G6PD deficiency.

• Hepatic impairment: Use with caution in patients with severe hepatic impairment.

• Renal impairment: Use with caution in patients with severe renal impairment.

• Respiratory disease: Use with caution in patients with preexisting respiratory compromise (hypoxia and/or hypercapnia), chronic obstructive pulmonary disease, or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.

Special populations:

• Older adult: Use with caution in older adults.

Other warnings/precautions:

• Appropriate use: Because barbiturates have been associated with medication-overuse headache, reserve use for patients without alternative treatment options (EFNS [Bendtsen 2010]; Kaniecki 2012). If used, limit butalbital use to ≤3 days per month to avoid medication-overuse headache (Garza 2006); studies have found increased risk with use of ≥5 days per month (Da Silva 2014).

• Discontinuation of therapy: When discontinuing chronic or high-dose treatment with butalbital, or if a patient has developed chronic migraine on butalbital, discontinuing butalbital and replacing with a gradual phenobarbital taper is advised to avoid barbiturate withdrawal symptoms (ie, anxiety, diaphoresis, disturbed sleep, nausea/vomiting, restlessness, seizures, worsened headache). These patients will likely require bridge therapy with a medication to treat acute headaches and may benefit from an optimized preventative regimen (Boes 2006; Garza 2025).

• Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to <4 g/day.

Warnings: Additional Pediatric Considerations

Hepatoxicity has been reported in patients using acetaminophen. In pediatric patients, this is most commonly associated with supratherapeutic dosing, more frequent administration than recommended, and use of multiple acetaminophen-containing products; however, hepatotoxicity has been rarely reported with recommended dosages (AAP [Sullivan 2011]; Heard 2014). All sources of acetaminophen (eg, prescription, OTC, combination) should be considered when evaluating a patient's maximum daily dose. To lower the risk for hepatotoxicity, the maximum daily acetaminophen dose should be limited to ≤75 mg/kg/day (maximum of 5 daily doses), not to exceed 4,000 mg/day (AAP [Sullivan 2011]; Heard 2014; Krenzelok 2012; Lavonas 2010). Acetaminophen avoidance or a lower total daily dose (2,000 to 3,000 mg/day) has been suggested for adults with increased risk for acetaminophen hepatotoxicity (eg, malnutrition, certain liver diseases, use of drugs that interact with acetaminophen metabolism); similar data are unavailable in pediatric patients (Hayward 2016; Larson 2007; Worriax 2007).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Generic: Butalbital 50 mg and acetaminophen 300 mg

Tablet, Oral:

Allzital: Butalbital 25 mg and acetaminophen 325 mg

Bupap: Butalbital 50 mg and acetaminophen 300 mg [DSC] [contains fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Generic: Butalbital 50 mg and acetaminophen 300 mg, Butalbital 50 mg and acetaminophen 325 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Butalbital-Acetaminophen Oral)

50-300 mg (per each): $14.55

Tablets (Allzital Oral)

25-325 mg (per each): $4.70

Tablets (Butalbital-Acetaminophen Oral)

50-300 mg (per each): $1.13 - $14.55

50-325 mg (per each): $1.55 - $1.56

Tablets (Tencon Oral)

50-325 mg (per each): $0.80

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Controlled Substance

C-III or nonscheduled (DEA exemption status dependent)

Administration: Pediatric

Oral: May take without regard to food; if GI upset occurs, may take with food.

Storage/Stability

Store at 20ºC to 25ºC (68ºF to 77ºF). Protect from light and moisture.

Use

Treatment of tension or muscle contraction headache (FDA approved in ages ≥12 years and adults)

Medication Safety Issues
Sound-alike/look-alike issues:

Butalbital and acetaminophen may be confused with butalbital, acetaminophen, and caffeine; and butalbital, acetaminophen, caffeine, and codeine.

Older Adult: High-Risk Medication:

Beers Criteria: Butalbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2023]).

Other safety concerns:

Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Alcohol (Ethyl): May increase hepatotoxic effects of Acetaminophen. Risk C: Monitor

Atazanavir: May increase serum concentration of UGT1A1 Substrates. Management: Do not use UGT1A1 substrates for which small increases in exposure can cause serious adverse effects together with atazanavir, and use caution with any UGT1A1 substrate, even when small changes in exposure are less likely to cause serious adverse effects. Risk D: Consider Therapy Modification

Belumosudil: May increase serum concentration of UGT1A1 Substrates. Management: Avoid coadministration of belumosudil with substrates of UGT1A1 for which minimal concentration increases can cause serious adverse effects. If coadministration is required, dose reductions of the UGT1A1 substrate may be required. Risk D: Consider Therapy Modification

Blood Pressure Lowering Agents: Barbiturates may increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Busulfan: Acetaminophen may increase serum concentration of Busulfan. Risk C: Monitor

CarBAMazepine: May increase metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. Risk C: Monitor

Dapsone (Topical): May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Risk C: Monitor

Dasatinib: Acetaminophen may increase hepatotoxic effects of Dasatinib. Dasatinib may increase serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and dasatinib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure. Risk D: Consider Therapy Modification

Doxycycline: Barbiturates may decrease serum concentration of Doxycycline. Risk C: Monitor

Flucloxacillin: May increase adverse/toxic effects of Acetaminophen. Specifically, the risk for high anion gap metabolic acidosis may be increased. Risk C: Monitor

Fosphenytoin-Phenytoin: May decrease serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). Risk C: Monitor

Griseofulvin: Barbiturates may decrease serum concentration of Griseofulvin. Risk C: Monitor

Hemin: Barbiturates may decrease therapeutic effects of Hemin. Risk X: Avoid

Imatinib: Acetaminophen may increase hepatotoxic effects of Imatinib. Risk C: Monitor

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Acetaminophen may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Isoniazid: May increase hepatotoxic effects of Acetaminophen. Isoniazid may increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

LamoTRIgine: Acetaminophen may decrease serum concentration of LamoTRIgine. Risk C: Monitor

Local Anesthetics: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Lorlatinib: May decrease serum concentration of Acetaminophen. Risk C: Monitor

Methoxyflurane: Barbiturates may increase nephrotoxic effects of Methoxyflurane. Barbiturates may increase metabolism of Methoxyflurane. Risk X: Avoid

MetyraPONE: May increase serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. Risk X: Avoid

Mianserin: May increase CNS depressant effects of Barbiturates. Mianserin may decrease therapeutic effects of Barbiturates. Barbiturates may decrease serum concentration of Mianserin. Risk X: Avoid

Mitapivat: May decrease serum concentration of UGT1A1 Substrates. Risk C: Monitor

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease serum concentration of Barbiturates. Risk C: Monitor

Nitric Oxide: May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Oxybate Salt Products: Barbiturates may increase CNS depressant effects of Oxybate Salt Products. Risk X: Avoid

PHENobarbital: May increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

Phenylephrine (Systemic): Acetaminophen may increase serum concentration of Phenylephrine (Systemic). Risk C: Monitor

Prilocaine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor

Primaquine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Primaquine. Specifically, the risk for methemoglobinemia may be increased. Management: Avoid concomitant use of primaquine and other drugs that are associated with methemoglobinemia when possible. If combined, monitor methemoglobin levels closely. Risk D: Consider Therapy Modification

Primidone: May increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

Probenecid: May increase serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses. Risk D: Consider Therapy Modification

RifAMPin: May increase hepatotoxic effects of Acetaminophen. RifAMPin may decrease serum concentration of Acetaminophen. Risk C: Monitor

Sodium Nitrite: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

SORAfenib: Acetaminophen may increase hepatotoxic effects of SORAfenib. SORAfenib may increase serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and sorafenib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure. Risk D: Consider Therapy Modification

Theophylline Derivatives: Barbiturates may decrease serum concentration of Theophylline Derivatives. Risk C: Monitor

Tricyclic Antidepressants: Barbiturates may increase metabolism of Tricyclic Antidepressants. Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required. Risk D: Consider Therapy Modification

Vaccines: Acetaminophen may decrease therapeutic effects of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination. Risk D: Consider Therapy Modification

Valproic Acid and Derivatives: May increase CNS depressant effects of Barbiturates. Valproic Acid and Derivatives may increase serum concentration of Barbiturates. Barbiturates may decrease serum concentration of Valproic Acid and Derivatives. Risk C: Monitor

Vitamin K Antagonists: Barbiturates may increase metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60% may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction. Risk D: Consider Therapy Modification

Pregnancy Considerations

Butalbital crosses the placenta (Ostrea 1982).

Outcome data following maternal use of butalbital during pregnancy are limited (Browne 2014; Heinonen 1977). Withdrawal seizures were reported in an infant 2 days after birth following maternal use of a butalbital product during the last 2 months of pregnancy; butalbital was detected in the newborn’s serum (Ostrea 1982).

The use of combination products containing butalbital are not recommended for the treatment of headache during pregnancy due to the increased risk of overuse headache, lack of supplemental analgesia, and increased risk of addiction and potential for congenital malformations (ACOG 2022).

Also refer to acetaminophen monograph for information specific to acetaminophen.

Mechanism of Action

Butalbital: Short- to intermediate-acting barbiturate; depresses the sensory cortex, decreases motor activity, alters cerebellar function, and produces drowsiness, sedation, hypnosis, and dose-dependent respiratory depression.

Acetaminophen: Although not fully elucidated, the analgesic effects are believed to be due to activation of descending serotonergic inhibitory pathways in the CNS. Interactions with other nociceptive systems may be involved as well (Smith 2009). Antipyresis is produced from inhibition of the hypothalamic heat-regulating center.

Pharmacokinetics (Adult Data Unless Noted)

Also see Acetaminophen monograph.

Absorption: Butalbital: Well absorbed

Protein binding: Butalbital: 45%

Half-life elimination: Butalbital: ~35 hours

Excretion: Butalbital: Urine (59% to 88% as unchanged drug or metabolites)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (PR) Puerto Rico: Allzital | Axocet | Bucet | Bupap | Butalbital and acetaminophen | Cephadyn | Orbivan cf | Phrenilin | Repan-cf | Sedapap | Tencon
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Allzital (butalbital and acetaminophen) [prescribing information]. Canton, MS: Larken Laboratories Inc; September 2020.
  3. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf. 2007;6(4):341-355. doi:10.1517/14740338.6.4.341 [PubMed 17688378]
  4. American College of Obstetricians and Gynecologists (ACOG). ACOG Clinical Practice Guideline No. 3: Headaches in pregnancy and postpartum. Obstet Gynecol. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766 [PubMed 35576364]
  5. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J; EFNS. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol. 2010;17(11):1318-1325. doi:10.1111/j.1468-1331.2010.03070.x [PubMed 20482606]
  6. Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol. 2006;26(2):232-241. [PubMed 16628534]
  7. Browne ML, Van Zutphen AR, Botto LD, Louik C, Richardson S, Druschel CM. Maternal butalbital use and selected defects in the national birth defects prevention study. Headache. 2014;54(1):54-66. doi:10.1111/head.12203 [PubMed 24001268]
  8. Bupap (acetaminophen/butalbital) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.
  9. Butalbital and acetaminophen [prescribing information]. Pine Brook, NJ: Alvogen Inc; October 2018.
  10. Chou R. Management of subacute and chronic low back pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 12, 2021.
  11. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy. 2007;27(9):1219-1230. doi:10.1592/phco.27.9.1219. [PubMed 17723075]
  12. Da Silva AN, Lake AE 3rd. Clinical aspects of medication overuse headaches. Headache. 2014;54(1):211-217. doi:10.1111/head.12223. [PubMed 24116964]
  13. Garza I. Medication overuse headache: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 11, 2025.
  14. Garza I, Swanson JW. Answers to frequently asked questions about migraine. Mayo Clin Proc. 2006;81(10):1387-1391. doi: 10.4065/81.10.1387. [PubMed 17036564]
  15. Hamilton JP, Goldberg E, Chopra S. Management of pain in patients with advanced chronic liver disease or cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 25, 2019.
  16. Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016;81(2):210-222. doi:10.1111/bcp.12802 [PubMed 26460177]
  17. Heard K, Bui A, Mlynarchek SL, et al. Toxicity from repeated doses of acetaminophen in children: assessment of causality and dose in reported cases. Am J Ther. 2014;21(3):174-183. [PubMed 22407198]
  18. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Publishing Sciences Group Inc. 1977.
  19. Kaniecki RG. Tension-type headache. Continuum (Minneap Minn). 2012;18(4):823-834. doi:10.1212/01.CON.0000418645.32032.32 [PubMed 22868544]
  20. Krenzelok EP, Royal MA. Confusion: acetaminophen dosing changes based on NO evidence in adults. Drugs R D. 2012;12(2):45-48. doi:10.2165/11633010-000000000-00000 [PubMed 22530736]
  21. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11(3):525-548. doi:10.1016/j.cld.2007.06.006 [PubMed 17723918]
  22. Lavonas EJ, Reynolds KM, Dart RC. Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. Pediatrics. 2010;126(6):e1430-e1444. [PubMed 21098156]
  23. Ostrea EM Jr. Neonatal withdrawal from intrauterine exposure to butalbital. Am J Obstet Gynecol. 1982;143(5):597-598. [PubMed 7201243]
  24. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician. 2009;12(1):269-280. [PubMed 19165309]
  25. Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011;127(3):580-587. [PubMed 21357332]
  26. Vohra V, Marraffa JM. Maternal use of acetaminophen-butalbital-caffeine product resulting in neonate butalbital exposure through breast milk. 39th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 21-24 May 2019, Naples, Italy. Clin Toxicol. 2019;57:549. doi:10.1080/15563650.2019.1598646
  27. Worriax JD, Yates JE, Flake D, Saseen JJ. Clinical inquiries. Alcoholic liver disease: is acetaminophen safe?. J Fam Pract. 2007;56(8):673-674. [PubMed 17669296]
Topic 118591 Version 246.0